Last reviewed · How we verify
BioLineRx, Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
3 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Autoimmune diseases · 1
- Nephrology · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie · 1 shared drug class
- Archigen Biotech Limited · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Bright Minds Biosciences Pty Ltd · 1 shared drug class
- Cardiovascular Clinical Sciences Inc · 1 shared drug class
- Celtic Pharma Development Services · 1 shared drug class
- Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
- Eric Stephen Winer, MD · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for BioLineRx, Ltd.:
- BioLineRx, Ltd. pipeline updates — RSS
- BioLineRx, Ltd. pipeline updates — Atom
- BioLineRx, Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). BioLineRx, Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biolinerx-ltd. Accessed 2026-06-09.